This article presents a cost-effectiveness analysis of nivolumab vs docetaxel from the US payer perspective in non–small cell lung cancer (NSCLC) based on randomized phase 3 studies with a minimum 5 years of follow-up.
Nadine Hertel, MBA
Advertisement
Articles by Nadine Hertel, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Inside Myeloma’s Evolution From Death Sentence to Cure
3
Evolocumab Cuts Death Risk for a First Heart Attack or Stroke
4
FDA Approves Ropeginterferon Alfa-2b in Essential Thrombocythemia
5